Companies

Companies

The latest research, products, and discoveries from the science industry’s leading companies and company divisions.

  • ALL
  • |
  • A
  • |
  • B
  • |
  • C
  • |
  • D
  • |
  • E
  • |
  • F
  • |
  • G
  • |
  • H
  • |
  • I
  • |
  • J
  • |
  • K
  • |
  • L
  • |
  • M
  • |
  • N
  • |
  • O
  • |
  • P
  • |
  • Q
  • |
  • R
  • |
  • S
  • |
  • T
  • |
  • U
  • |
  • V
  • |
  • W
  • |
  • X
  • |
  • Y
  • |
  • Z
  • Inscripta is developing the world's first benchtop platform for scalable digital genome engineering. The company's advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta's goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7™ CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, NanoDimension, MLS Capital, JS Capital Management LLC, and Oak HC/FT. For more information, visit www.inscripta.com.
    Illumina is transforming human health as the global leader in sequencing and array-based technologies. Illumina's flexible and scalable sequencing systems support and enable a wide range of single-cell sequencing applications, from low-throughput deep interrogation of rare cell populations to high-throughput profiling of tissues. For more information, please visit www.illumina.com.
    IONPATH IS REVOLUTIONIZING THE ANALYSIS OF TISSUE BIOPSIES WITH MULTIPLEXED ION BEAM IMAGING